本報告已在2011年07月19日停止出版。
生技晶片擁有分子層級的診斷與縮短藥物研發過程的潛力，但仍有些醫院懷疑其臨床實用性，價格高昂也是阻擋其商業化進展的要素之一。
專研高科技領域諮詢市調的美國專業公司 Frost &Sullivan (總公司: 德州)，調查分析了歐洲臨床研究用生物晶片市場後，出版了一本綜合報告書"European Market for Biochips in Clinical Research Applications"。
報告書內容包括：市場主要趨勢、各部門市場營收、各廠商市佔率、競爭結構等等，內容綱要摘記如下：
1. 摘要
2. 用語集與匯率
3. 整體生物晶片市場
- 市場概要
- 市場區分
- 市場策劃分析
- 生物晶片市場成長促進要素
- 生物晶片市場成長阻礙因素與課題
- 歐洲整體營收預測
- 技術面趨勢
- 競爭結構
- 終端用戶趨勢
4. DNA 晶片
5. 蛋白質晶片
6. Frost & Sullivan Award
7. 策略性建議
8. 決策支援資料庫
- 生技領域研發政府支出
- 醫藥研發支出
- 生技企業與員工數
- 生技領域的民間投資
9. 主要企業資料庫
Abstract
High Costs Prove a Hurdle to Commercial Adoption
Biochips have emerged as the buzzword in modern day medicine, especially after exhibiting their
immense potential in understanding disease pathways at the molecular level. While major scientific
breakthroughs in this field offer great value addition to changing the paradigm of diagnostics, many
hospitals remain sceptical of investing in these diagnostic kits without knowing their clinical
utility. Also, despite the potential to commercialise drugs faster, their premium pricing does not
justify the use of biochips in routine research processes. Companies are however striving towards
making biochips more affordable and with the combined efforts of research units and regulatory
bodies, pricing could be made more feasible for hospitals in medium to long term.
This Frost & Sullivan research service examines the European markets for biochips in clinical
research. It analyses the competitive structure and provides strategic recommendations to overcome
technical and business challenges confronting the adoption of these applications. The research
service also presents valuable end-user feedback that can help companies better tailor their product
offerings.
Flexibility of Chip Technology and Multi-parameter Testing Drive Uptake in Clinical Research
In this age of bio revolution, biochips offer the ability to identify and prioritise drug targets
through the parallel corroboration of a multitude of gene expressions. The concept of expanding
information content by shrinking feature seize is also being probed using technical knowledge
borrowed from the semiconductor industry. "With the recent Food and Drug Administration (FDA)
guidelines on pharmacogenomics, it is anticipated that there would be steady growth in the biochips
market," says the analyst of this research service. "Companies can expect to see a boost
in their revenues and market share if they focus on developing disease-specific biomarkers with
genomics/proteomics technology."
The biochips market is witnessing a shift in strategies wherein the established array companies
are looking to gain better penetration rates by collaborating with firms that own biocontent. Recent
alliances in the global markets are expected to have a significant impact on the European market as
they bring together companies with key intellectual properties and adequate financial resources.
With the trend towards strategic alliances, a balanced combination of collaboration strategies,
contracts and pricing is likely to make the DNA market more feasible for use in elaborate laboratory
experimentation.
Personalised Medicine Holds Promise for Future Development
Personalised medicine -- a concept that promises to individualise diagnosis -- is expected to
slowly make its presence in the commercial diagnostic segment. Although this is a positive driver
for the growth of array technologies in clinical diagnostics, the critical hurdle lies in obtaining
consistent and statistically relevant readouts. This calls for systems that are easy to use and are
equipped with robust infrastructure to provide consistent results in the clinical research phase.
Although the novel and radical concept of personalised medicine is expected to alter the nature of
diagnostics in the future, its impact on the commercial market is likely to be more profound in the
medium to long run.
Companies strongly feel biochip technologies need to address relevant research questions in order
to be commercialised in diagnostics. "At present, biochip technologies employed in clinical
diagnostics are thought to account for only around 10 per cent of all biochip applications with the
remainder being used in drug discovery applications," says the analyst. "Most companies
are employing open platforms in their biochips since this helps boost revenues and ensures healthy
dividends that compensate the high research and development (R&D) costs involved in enabling
these technologies."
Table of Contents
- 1. Executive Summary
- 2. Glossary & Exchange Rates
- 1. Glossary and Exchange Rates
- 1. Glossary of Terms
- 2. Exchange Rates
- 3. Total Biochips Market
- 1. Market Overview
- 2. Segmentation
- 3. Market Engineering Measurements for Biochips Market- Clinical Research Applications
- 1. Market Engineering Measurements
- 4. Biochip Market Drivers
- 1. Market Drivers
- a. Miniaturisation and Multi-parameter Tests
- b. Strategic Alliances
- c. Turn Around Time
- d. Personalised Medicine - For a Healthier Tomorrow
- e. High Throughput Systems & Human Genome Research
- f. Disease Pathologies Encourage Employment of Protein Arrays
- 5. Market Restraints/Challenges
- 1. Market Restraints/Challenges
- a. Cost: The major Downside to the Growth of these Biochip Techniques for Clinical Diagnostic
Applications
- b. Standardisation of Gene Data Pool
- c. Reimbursement Climate
- d. Technology Transfer from Bench to Bedside
- e. Content Customisation
- f. Manufacturing Processes Involve High Costs and Time
- g. Data Comparison Across Platforms
- h. Unavailability of Capture Agents: A Major Stumble Block
- i. Drug Targets Seek the Aid of Protein Chips
- j. Long-term Safety Studies
- 6. Total European Revenue Forecasts
- 7. Technological Trends
- 8. Competitive Landscape
- 9. End-user Trends
- 4. DNA Chips
- 1. Introduction
- 2. Market Engineering Measurements
- 1. Market Engineering Measurements
- 3. Market Revenue Forecasts
- 4. Competitive Landscape
- 5. Protein Chips
- 1. Introduction
- 2. Market Engineering Measurements
- 1. Market Engineering Measurements
- 3. Market Revenue Forecasts
- 4. Competitive Landscape
- 6. Frost & Sullivan Awards
- 1. Frost & Sullivan Awards for the European Biochips Market -Clinical Research Applications
- 1. Frost & Sullivan Award Description
- 2. Product Quality Innovation Award
- 3. Technology Innovation Award
- 7. Strategic Recommendations
- 1. Strategic Recommendations for Challenges that confront Biochips in Clinical Research
- 8. DSD for Biochips in Clinical Research Applications
- 1. Government R&D Expenditure
- 1. R&D Investment in Biotechnology
- 2. Pharmaceutical R&D Expenditure
- 1. Pharmaceutical R&D Expenditure
- 3. Biotech Companies and Number of Employees
- 1. Biotech Companies
- 2. Number of Employees
- 4. Private Investment in Biotechnology
- 1. Private Investment in Biotechnology
- 9. Database of Key Industry Participants(DKIP)
- 1. Key Industry Participants
- 1. Database of Key Industry Participants
